Taysha Gene Therapies Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
8.3%projected annual EPS growth
Analyst Coverage
12analysts covering
FY EPS (est.)
-$0.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 12 Nov 2026 |
| REVEAL Pivotal Trial 6-Month Interim Data Update | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
TSHA-102 REVEAL Pivotal Trial Response Rate Quarterly10,000.0%Target: Maintain high response rate (percentage of patients gaining or regaining >=100 of 28 natural history-defined developmental milestones)%
Cash and Cash Equivalents Quarterly276.6MTarget: Sufficient to fund planned operating expenses into 2028
TSHA-102 Safety Profile (Treatment-Related SAEs or DLTs) Quarterly0.0Target: 0 treatment-related serious adverse events or dose-limiting toxicities
Watch Items
- TSHA-102 REVEAL Pivotal Trial 6-Month Interim DataTrigger: Late 2026 data releaseAction: Evaluate efficacy and safety data to confirm readiness for BLA submission
- Process Performance Qualification (PPQ) Campaign CompletionTrigger: Expected completion by Q4 2026Action: Verify CMC alignment with clinical development timelines to support planned BLA package
- FDA Alignment on BLA Submission PathwayTrigger: Post-interim data review with FDAAction: Confirm FDA acceptance of 6-month interim analysis as the basis for BLA filing
Research as of 20 Jun 2026